Computer modeling shows how medications play a part in the Parkinson's experience

September 11, 2012

(Medical Xpress)—A University of Western Sydney researcher has developed a new computational model, which will improve our understanding of how Parkinson's disease (PD) medications affect the brain and cognition.

Dr Ahmed Moustafa, from the School of Social Sciences and Psychology and the MARCS Institute at UWS, says the primary symptoms of PD are thought to be the result of the insufficient formation and action of Dopamine.

"Dopamine is one of the neurotransmitters responsible for the way the human brain processes information," says Dr Moustafa.

"When Parkinson's patients experience symptoms of motor skill and cognitive dysfunction – such as muscle rigidity, tremors and a slowing of physical movement – it is believed that the disease has impaired the ability of their brains to produce this important chemical that led to the motor and ."

Along with colleagues Dr Mohammad Herzallah and Dr Mark Gluck from the Center for Neuroscience at Rutgers University, Dr Moustafa has devised a method of tracking the various affects of key Dopamine replacement therapies – such as Levodopa, and Ropinirole.

The 'computational model', to be published in the journal, provides a mechanistic account of several positive and negative effects of PD treatments.

Dr Moustafa says the key effect appears to lie within the activation of the D1 and D2 receptors.

"It appears that that the differential effects of dopamine medications are related to their binding to D1 and D2 receptors. It seems that these medications have variable effects on D1 receptors," says Dr Moustafa.

"By tracking how these different treatments affect different , we have been able to explain why some PD patients experience some very different ."

Dr Moustafa says treatments such as Levodopa, which produce added Dopamine by over stimulating the motor neurons, appear to have a higher affinity with these D1 receptors.

"Clinical research shows that the chronic administration of Levodopa can enhance ' cognition, but can also lead to a phenomenon known as Levodopa-induced Dyskinesia – a disorder which causes patients to have involuntary movements, most commonly in the upper body," he says.

"Other treatments, which do not activate the D1 receptors, do not have the same effects."

Dr Moustafa's will have wide-ranging implications for understanding the varied physical effects of Parkinson's disease, as well as the potential side-effects of Parkinson's medications.

"Clinical research also shows that a subset of Parkinson's patients develops what is known as impulse control disorders, which involve pathological gambling, hypersexuality, and binge eating," says Dr Moustafa.

"Basically, the brain's difficulty in processing information eventually impairs the patient's ability to learn to avoid negative outcomes – including gaining weight, and losing jobs, money and relationships.

"If the development of these impulse control disorders can be conclusively traced to the overstimulation of , it may be possible to understand why some Parkinson's patients develop impulse control disorders, and others do not – and then to regulate the medications that stimulate these specific receptors."

Related Stories

Recommended for you

Parkinson's is partly an autoimmune disease, study finds

June 21, 2017
Researchers have found the first direct evidence that autoimmunity—in which the immune system attacks the body's own tissues—plays a role in Parkinson's disease, the neurodegenerative movement disorder. The findings raise ...

Predicting cognitive deficits in people with Parkinson's disease

June 20, 2017
Parkinson's disease (PD) is commonly thought of as a movement disorder, but after years of living with PD approximately twenty five percent of patients also experience deficits in cognition that impair function. A newly developed ...

Pre-clinical study suggests Parkinson's could start in gut endocrine cells

June 15, 2017
Recent research on Parkinson's disease has focused on the gut-brain connection, examining patients' gut bacteria, and even how severing the vagus nerve connecting the stomach and brain might protect some people from the debilitating ...

Hi-res view of protein complex shows how it breaks up protein tangles

June 15, 2017
Misfolded proteins are the culprits behind amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, and other neurodegenerative brain disorders. These distorted proteins are unable to perform their normal ...

CRISPR tech leads to new screening tool for Parkinson's disease

June 5, 2017
A team of researchers at the University of Central Florida is using breakthrough gene-editing technology to develop a new screening tool for Parkinson's disease, a debilitating degenerative disorder of the nervous system. ...

Infection with seasonal flu may increase risk of developing Parkinson's disease

May 30, 2017
Most cases of Parkinson's have no known cause, and researchers continue to debate and study possible factors that may contribute to the disease. Research reported in the journal npj Parkinson's Disease suggests that a certain ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.